Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing therapies. The Company concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The Company's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. It is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.